TEL AVIV, Israel and BETHESDA, Maryland, Sep 13, 2021
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX),a global leader in the development of cancer related cannabinoid-based medicine and a pioneer in the development of psychedelic inspired medicine, announced today that Dr. Ilya Reznik (MD), a renowned Neuropsychiatrist, has joined the company as Head of Psychedelic Inspired Medicine.
The nomination of Dr. Reznik is part of the company’s strategy to develop new psychedelic inspired medicines and therapies to address several mental health related conditions. The announcement follows the company’s recent launching of a Psilocybin and Psilocin Research Program taking place under license by Israeli Ministry of Health.
Eyal Barad, Cannabics Pharmaceuticals’ CEO, commented: “It is with great pleasure that I welcome Dr. Reznik to our team. Dr. Reznik is a world-renowned Neuropsychiatrists with ample experience and accomplishments in his field of specialty, including having conducted research using psychedelic compounds. I look forward to working with him, and I am certain that he will help drive the company’s psychedelic inspired development program forward successfully.”
Dr. Ilya Reznik commented: “It is a great honor to have been invited to join the team of Cannabics Pharmaceuticals, a well-known leader in the field of cannabinoid-based medicine development. The company’s established facilities, experience and knowhow, are an excellent foundation upon which we will now build a new development program for Psychedelic Inspired Medicine, and I look forward to working with the Cannabics team in making this a successful venture that could potentially help large groups of patients suffering from various mental conditions with unmet needs.”
About Dr. Reznik:
Dr. Ilya Reznik is a Board-certified specialist in Adult Forensic & Clinical NeuroPsychiatry at MaReNa Diagnostic and Consulting Center, Israel.
Dr. Ilya Reznik has superior educational and professional record and documented contributions to the field of neuropsychiatric research, such as publications and other innovative activities. Dr. Reznik has published numerous original papers, including controlled clinical trials, reviews and case reports in leading peer-reviewed journals in field of clinical psychiatry and neuropsychopharmacology.
Dr. Reznik’s current main interest is in the field of the medicinal use of cannabis and cannabinoids, especially for various neuropsychiatric illnesses, such as Chronic Pain Syndrome, Fibromyalgia, Post-Traumatic Stress Disorder (PTSD), Epilepsy, Head/Brain Injury, OCD, ADHD, Gilles de la Tourette syndrome, Chronic Headache, Parkinson’s and Alzheimer diseases etc.
During the last 12 years Dr. Reznik gained an extensive clinical & research experience working with cannabis and its products in Neuropsychiatry and General & Complementary/Integrative Medicine. He coordinated the activity of Israel National Forum for Medical Cannabis Research & Treatment and served as a professional advisor (and permanent participant and observer) to the Israeli Parliament (Knesset) Committee for Drugs and Alcohol Control and to the Parliamentary Public Lobby for Medicinal Cannabis.
Dr. Reznik is a renowned International Speaker on Cannabinoid Medicine issues. He is an Associate Member of The Canadian Consortium for the Investigation of Cannabinoids (CCIC) & of the International Cannabinoid Research Society (ICRS). In 2013 he was elected to the Board of Directors, International Association for Cannabinoid Medicines (IACM).
In 2019 Dr. Ilya Reznik was appointed as IACM Secretary for Partnership & Networking and promotes Educational and International activity within IACM.
Recent expansion of Cannabics Pharmaceuticals’ Board of Advisors to include: Prof. Caroline Robert (MD, Ph.D.), a Melanoma expert, and, Dr. Sigal Tavor (MD), a Hematology expert, along with Prof. Amos Toren (MD), Prof. Zamir Halpern (MD), Prof. Noam Shomron (Ph.D.), Dr. Erez Scapa (MD), Dr. Dana Ben-Ami Shor (MD), Dr. Sigalit Arieli-Portnoy (Ph.D.) and Dr. Tal Mofkadi (Ph.D.).
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those outlined in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission including, without limitation, our latest 10-Q Report filed July 14th, 2021. We undertake no duty to update any forward-looking statement or any information contained in this press release or other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc., which are condoned by the Company, must emanate from the Company itself and bear our name as its source.